A Phase 2 interventional study of Laser Photocoagulation and Intravitreal Aflibercept Injection in Diabetic Macular Edema, sponsored by Regeneron Pharmaceuticals. Completed at 47 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-09.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies testing aflibercept in Macular Edema — 1 open to participants now, 3 under way, 1 of them phase 3. aflibercept · Macular Edema.
Among the 53 studies testing aflibercept in Macular Edema, this one is the 10th largest by enrollment, is the only one that started in 2008, is one of 7 in phase 2, and was the 2nd registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →1 of the 53 studies testing aflibercept in Macular Edema is open now, in 1 country. Recruiting first, the newest first:
CMH Multan Institute of Medical Sciences · Sites in Pakistan
Ages 30–60
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 12 · Phase 4 26
First in 2006; this study’s year is marked. 1 started in 2008.
This study's enrollment of 221 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 49 across the 53 interventional studies. Of the 36 that completed or were terminated, 18 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 53 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 7 studies filed under Macular Edema — fewer than ten, so there is no comparison to draw.
1 of the studies testing aflibercept in Macular Edema that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02645266McMaster UniversityMean Visual Acuity Changes Following Five Injections of Aflibercept | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 53 studies testing aflibercept in Macular Edema, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, doubled-masked, randomized study of the efficacy and safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in subjects with diabetic macular edema (DME). Approximately 200 subjects will be randomized in the US, Canada, Australia and EU.
Qualified subjects will be randomized to one of 5 treatment arms. The active (treatment) phase of the study will be 52 weeks, with a 6 month safety follow-up
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) .5 mg every 4 weeks
Drug: Intravitreal Aflibercept Injection
Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2 mg every 4 weeks
Drug: Intravitreal Aflibercept Injection
Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2mg every 4 weeks for 3 visits followed by every 8 weeks
Drug: Intravitreal Aflibercept Injection
Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2mg every 4 weeks for 3 visits followed by PRN (as-needed) dosing according to the re-treatment criteria
Drug: Intravitreal Aflibercept Injection
Focal laser at week 1, and one week after visits at which the participant met laser re-treatment criteria to the end of the study (week 52) starting at week 16; laser re- treatment was permitted no more than once every 16 weeks.
Procedure: Laser Photocoagulation
laser every 16 weeks as needed
Also known as: macular laser therapy
Also known as: IAI; EYLEA®; BAY86-5321; VEGF Trap-Eye
Change in BCVA From Baseline to Week 24 - Last Observation Carried Forward (LOCF)
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. Measurements were taken at every study visit. Missing values were imputed with post-baseline values during on-treatment period by using last observation carried forward (LOCF).
Time frame: At week 24
Change in BCVA From Baseline to Week 52 - LOCF
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. Missing values were imputed with post-baseline values during on-treatment period by using last observation carried forward (LOCF).
Time frame: At week 52
Participants With Gains in ETDRS Letter Score of at Least 15 Letters - LOCF
Missing values were imputed with post-baseline values during on-treatment period by using last observation carried forward (LOCF).
Time frame: At week 24 and week 52
Change From Baseline in Central Retinal Thickness (CRT) as Assessed by Optical Coherence Tomography (OCT) - LOCF
Retinal thickness was evaluated using OCT at every visit except week 1. Missing values were imputed with post-baseline values during on-treatment period by using last observation carried forward (LOCF).
Time frame: At week 24 and week 52
Number of Focal Laser Treatments
Time frame: Week 1 to week 48
A total of 221 participants were randomized at 39 sites in the US, Canada, and Austria. After the 1 year treatment period, participants were to be followed for safety in a 6 mo. follow-up phase. The last visit for this study occurred in September, 2010.
| Milestone | Laser Photocoagulation | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321).5Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)2PRN |
|---|---|---|---|---|---|
| Started | 44 | 44 | 44 | 44 | 45 |
| Participants received treatment | 44 | 44 | 44 | 42 | 45 |
| Completed | 33 | 38 | 33 | 34 | 38 |
| Not completed | 11 | 6 | 11 | 10 | 7 |
| Withdrew: Withdrawal by subject | 2 | 1 | 3 | 2 | 3 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 3 | 3 | 1 | 0 | 0 |
| Withdrew: Death | 1 | 1 | 2 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 4 | 2 | 4 |
| Withdrew: Lack of efficacy | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 2 | 0 | 1 | 3 | 0 |
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. Measurements were taken at every study visit. Missing values were imputed with post-baseline values during on-treatment period by using last observation carried forward (LOCF).
| letters correctly read | Laser Photocoagulation | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321).5Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)2PRN |
|---|---|---|---|---|---|
| Change in BCVA From Baseline to Week 24 - Last Observation Carried Forward (LOCF) | 2.5 ± 16.14 | 8.6 ± 14.64 | 11.4 ± 8.67 | 8.5 ± 7.50 | 10.3 ± 7.52 |
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. Missing values were imputed with post-baseline values during on-treatment period by using last observation carried forward (LOCF).
| letters correctly read | Laser Photocoagulation | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321).5Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)2PRN |
|---|---|---|---|---|---|
| Change in BCVA From Baseline to Week 52 - LOCF | -1.3 ± 20.72 | 11.0 ± 15.40 | 13.1 ± 10.54 | 9.7 ± 8.93 | 12.0 ± 11.09 |
Missing values were imputed with post-baseline values during on-treatment period by using last observation carried forward (LOCF).
| participants | Laser Photocoagulation | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321).5Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)2PRN |
|---|---|---|---|---|---|
| At week 24 | 9 ± 135.17 | 15 ± 110.65 | 14 ± 143.04 | 7 ± 141.78 | 12 ± 132.17 |
| At week 52 | 5 | 18 | 20 | 10 | 19 |
Retinal thickness was evaluated using OCT at every visit except week 1. Missing values were imputed with post-baseline values during on-treatment period by using last observation carried forward (LOCF).
| microns | Laser Photocoagulation | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321).5Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)2PRN |
|---|---|---|---|---|---|
| At week 24 | -67.9 ± 135.17 | -144.6 ± 110.65 | -194.5 ± 143.04 | -127.3 ± 141.78 | -153.3 ± 132.17 |
| At week 52 | -58.4 ± 177.60 | -165.4 ± 135.72 | -227.4 ± 148.96 | -187.8 ± 135.01 | -180.3 ± 124.43 |
| Treatments | Laser Photocoagulation | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321).5Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)2PRN |
|---|---|---|---|---|---|
| Number of Focal Laser Treatments | 2.5 ± 0.87 | 0.8 ± 0.93 | 0.5 ± 0.66 | 0.8 ± 0.86 | 0.7 ± 0.77 |
Collected over Day 1 to week 52. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Laser Photocoagulation | — | 10/44 (22.7%) | 20/44 (45.5%) |
| Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321).5Q4 | — | 14/44 (31.8%) | 22/44 (50%) |
| Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 | — | 13/44 (29.5%) | 22/44 (50%) |
| Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 | — | 12/42 (28.6%) | 26/42 (61.9%) |
| Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)2PRN | — | 6/45 (13.3%) | 24/45 (53.3%) |
| Event | Laser Photocoagulation | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321).5Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)2PRN |
|---|---|---|---|---|---|
| Cardiac failure congestiveCardiac disorders | 0/44 | 0/44 | 3/44 | 1/42 | 2/45 |
| CellulitisInfections and infestations | 0/44 | 3/44 | 2/44 | 0/42 | 1/45 |
| Vitreous haemorrhageEye disorders | 3/44 | 0/44 | 0/44 | 0/42 | 0/45 |
| Chest painGeneral disorders | 0/44 | 0/44 | 2/44 | 0/42 | 3/45 |
| DehydrationMetabolism and nutrition disorders | 0/44 | 0/44 | 0/44 | 2/42 | 0/45 |
| Vitreous haemorrhageEye disorders | 1/44 | 1/44 | 1/44 | 2/42 | 0/45 |
| AnaemiaBlood and lymphatic system disorders | 0/44 | 1/44 | 2/44 | 0/42 | 0/45 |
| Cerebrovascular accidentNervous system disorders | 1/44 | 1/44 | 2/44 | 0/42 | 0/45 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/44 | 0/44 | 2/44 | 0/42 | 0/45 |
| HypertensionVascular disorders | 0/44 | 0/44 | 2/44 | 1/42 | 0/45 |
| Event | Laser Photocoagulation | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321).5Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)2PRN |
|---|---|---|---|---|---|
| Conjunctival haemorrhageEye disorders | 8/44 | 12/44 | 7/44 | 15/42 | 13/45 |
| Eye painEye disorders | 2/44 | 6/44 | 5/44 | 6/42 | 7/45 |
| Blood glucose increasedInvestigations | 1/44 | 4/44 | 3/44 | 6/42 | 6/45 |
| HypertensionVascular disorders | 5/44 | 5/44 | 5/44 | 6/42 | 5/45 |
| Glycosylated haemoglobin increasedInvestigations | 2/44 | 6/44 | 5/44 | 5/42 | 2/45 |
| Intraocular pressure increasedInvestigations | 1/44 | 6/44 | 6/44 | 5/42 | 2/45 |
| Ocular hyperaemiaEye disorders | 2/44 | 5/44 | 2/44 | 3/42 | 3/45 |
| Vitreous detachmentEye disorders | 5/44 | 3/44 | 3/44 | 3/42 | 0/45 |
| Vitreous floatersEye disorders | 2/44 | 5/44 | 3/44 | 2/42 | 2/45 |
| Vitreous haemorrhageEye disorders | 5/44 | 3/44 | 5/44 | 4/42 | 3/45 |
Full analysis set (FAS): included all randomized patients who received any study drug, had baseline assessments, and had at least one (1) post-baseline assessment.
| Age, Continuous(years) | Laser Photocoagulation | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321).5Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)2PRN | Total |
|---|---|---|---|---|---|---|
| Mean | 64.0 ± 8.12 | 62.3 ± 10.70 | 62.1 ± 10.50 | 62.5 ± 11.49 | 60.7 ± 8.66 | 62.3 ± 9.92 |
| Sex: Female, Male(Participants) | Laser Photocoagulation | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321).5Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)2PRN | Total |
|---|---|---|---|---|---|---|
| Female | 17 | 20 | 17 | 20 | 16 | 90 |
| Male | 27 | 24 | 27 | 22 | 29 | 129 |
The record gives a start of Dec 2008, a primary completion of Dec 2009 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2014, 4 years 9 months after primary completion. A results delay was requested in Apr 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept